Skip to main content
Fig. 1 | Experimental Hematology & Oncology

Fig. 1

From: Targeting CD22 for B-cell hematologic malignancies

Fig. 1

CD22 and CD22 CAR structure. A CD22 molecule and the recognized domain of different CD22 scFv and ADCs. B CD22 CAR structures in preclinical and clinical use. ITIM immunoreceptor tyrosine-based inhibitory motif. The image was created using BioRender (Biorender, Toronto, ON, Canada)

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us